Pembrolizumab plus olaparib vs enzalutamide or abiraterone in patients with metastatic castration-resistant prostate cancer who experienced progression on chemotherapy: phase 3 KEYLYNK-010 study

被引：0
|
作者：
Yu, Evan [1 ]
Park, Se Hoon [2 ]
Huang, Yi-Hsiu [3 ]
Bennamoun, Mostefa [4 ]
Xu, Lu [5 ]
Kim, Jeri [5 ]
Antonarakis, Emmanuel [6 ]
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Samsung Med Ctr, Seoul, South Korea
[3] Taipei Vet Gen Hosp, Taipei, Taiwan
[4] Inst Mutualiste Montsouris, Paris, France
[5] Merck & Co Inc, Kenilworth, NJ USA
[6] Johns Hopkins Univ, Baltimore, MD USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2019年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P390
引用
收藏
页数：2
相关论文
共 50 条
  • [1] PHASE 3 STUDY OF COMBINATION PEMBROLIZUMAB plus OLAPARIB THERAPY VERSUS ENZALUTAMIDE/ABIRATERONE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) AFTER PROGRESSION ON CHEMOTHERAPY (KEYLYNK-010)
    Yu, Evan
    Park, Se Hoon
    Huang, Yi-Hsiu
    Bennamoun, Mostefa
    Xu, Lu
    Kim, Jeri
    Antonarakis, Emmanuel
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A210 - A211
  • [2] Phase III study of pembrolizumab (pembro) plus olaparib versus enzalutamide (enza) or abiraterone acetate (abi) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who progressed on chemotherapy: KEYLYNK-010
    Yu, Evan Y.
    Park, Se Hoon
    Huang, Yi-Hsiu
    Bennamoun, Mostefa
    Xu, Lu
    Kim, Jeri
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [3] Pembrolizumab plus olaparib vs abiraterone (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC): Randomized open-label phase III KEYLYNK-010 study
    Yu, E. Y.
    Park, S. H.
    Goh, J. C. H.
    Shin, S. J.
    Mehra, N.
    McDermott, R.
    Sala Gonzalez, M. A.
    Fong, P. C.
    Greil, R.
    Retz, M.
    Sade, J. P.
    Huang, Y-H.
    Begbie, S.
    Rey, F.
    Kramer, G.
    Suzuki, H.
    Zhang, J.
    Kim, J.
    Poehlein, C. H.
    Antonarakis, E. S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1163 - S1164
  • [4] KEYLYNK-010: Phase III study of pembrolizumab (pembro) plus olaparib (OLA) vs enzalutamide (ENZA) or abiraterone (ABI) in ENZA- or ABI-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who had progression on chemotherapy (CTx)
    Yu, E.
    Xu, L.
    Kim, J.
    Antonarakis, E. S.
    ANNALS OF ONCOLOGY, 2019, 30
  • [5] Patient-reported outcomes (PROs) in KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) vs abiraterone acetate (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC).
    Mehra, Niven
    Antonarakis, Emmanuel S.
    Park, Se Hoon
    Goh, Jeffrey C.
    McDermott, Raymond S.
    Gonzalez, Nuria Sala
    Fong, Peter C. C.
    Greil, Richard
    De Santis, Maria
    Yanez, Patricio Eduardo
    Huang, Yi-Hsiu
    Begbie, Stephen
    Rey, Felipe
    Kramer, Gero
    Suzuki, Hiroyoshi
    Saretsky, Todd L.
    Ghate, Sameer R.
    Cui, Yi
    Kim, Jeri
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [6] Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial
    Antonarakis, Emmanuel S.
    Park, Se Hoon
    Goh, Jeffrey C.
    Shin, Sang Joon
    Lee, Jae Lyun
    Mehra, Niven
    McDermott, Ray
    Sala-Gonzalez, Nuria
    Fong, Peter C.
    Greil, Richard
    Retz, Margitta
    Sade, Juan Pablo
    Yanez, Patricio
    Huang, Yi-Hsiu
    Begbie, Stephen D.
    Gafanov, Rustem Airatovich
    De Santis, Maria
    Rosenbaum, Eli
    Kolinsky, Michael P.
    Rey, Felipe
    Chiu, Kun-Yuan
    Roubaud, Guilhem
    Kramer, Gero
    Sumitomo, Makoto
    Massari, Francesco
    Suzuki, Hiroyoshi
    Qiu, Ping
    Zhang, Jinchun
    Kim, Jeri
    Poehlein, Christian H.
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (22) : 3839 - +
  • [7] Abiraterone or Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer
    La, Jennifer
    Wang, Lin
    Corrigan, June K.
    Lang, Deborah
    Lee, Michelle H.
    Do, Nhan V.
    Brophy, Mary T.
    Paller, Channing J.
    Fillmore, Nathanael R.
    JAMA NETWORK OPEN, 2024, 7 (08)
  • [8] Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: phase 3 KEYNOTE-641 study
    Graff, Julie Nicole
    Burgents, Joseph
    Liang, Li Wen
    Stenzl, Arnulf
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [9] Abiraterone Followed by Enzalutamide Versus Enzalutamide Followed by Abiraterone in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer
    Matsubara, Nobuaki
    Yamada, Yoko
    Tabata, Ken-ichi
    Satoh, Takefumi
    Kamiya, Naoto
    Suzuki, Hiroyoshi
    Kawahara, Takashi
    Uemura, Hiroji
    Yano, Akihiro
    Kawakami, Satoru
    Otsuka, Masafumi
    Fukasawa, Satoshi
    CLINICAL GENITOURINARY CANCER, 2018, 16 (02) : 142 - 148
  • [10] Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression
    Becker, Daniel J.
    Iyengar, Arjun D.
    Punekar, Salman R.
    Ng, Jason
    Zaman, Anika
    Loeb, Stacy
    Becker, Kevin D.
    Makarov, Danil
    ANTICANCER RESEARCH, 2019, 39 (05) : 2467 - 2473
12345